Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06555796 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer
A Phase 1 study of Prostate Cancer and High-risk Biochemical Recurrence, sponsored by Amgen.
- Active
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 11
- Study locations
NCT06555796 is a Phase 1 study of Prostate Cancer and High-risk Biochemical Recurrence that is active but no longer recruiting, run by Amgen. The registered enrollment target is 50 participants, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (92% lower). The trial reports 11 study locations across 9 states.
The verdict
NCT06555796, a Phase 1 study of Prostate Cancer and High-risk Biochemical Recurrence, is active but no longer recruiting, sponsored by Amgen.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 11
- Study locations
Study Summary
The main objective of this study is to evaluate the safety and tolerability of xaluritamig monotherapy in adult participants with high-risk biochemical recurrent (BCR) nonmetastatic castration-sensitive prostate cancer (nmCSPC).
Conditions Studied
Interventions
- DRUG Xaluritamig
Study Locations (11)
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
- Levine Cancer Institute - Charlotte
Victoria
- Cabrini Hospital - Malvern
- Peter MacCallum Cancer Centre - Melbourne
Minnesota
- University of Minnesota Medical Center Fairview - Minneapolis
New York
- Memorial Sloan Kettering Cancer Center - New York
Oregon
- Oregon Health and Science University - Portland
Pennsylvania
- Thomas Jefferson University - Philadelphia
Texas
- University of Texas Southwestern Medical Center - Dallas
Washington
- Fred Hutchinson Cancer Center - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2024-09-23 |
| Est. Completion | 2028-12-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06555796
The ClinicalTrials.gov registry entry for NCT06555796 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 608-participant average among 735 other Prostate Cancer trials with a reported enrollment target (92% lower). The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Xaluritamig is the first listed.
NCT06555796 reports 11 study locations spanning 9 distinct geographic areas - top geographies include North Carolina, Victoria, Minnesota.
Frequently Asked Questions
What is clinical trial NCT06555796 about?
NCT06555796 is a clinical study titled "Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer". The main objective of this study is to evaluate the safety and tolerability of xaluritamig monotherapy in adult participants with high-risk biochemical recurrent (BCR) nonmetastatic castration-sensitive prostate cancer (nmCSPC).
What is the current status of trial NCT06555796?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2024-09-23. Estimated completion is 2028-12-02.
What conditions does trial NCT06555796 study?
This clinical trial studies the following conditions: Prostate Cancer, High-risk Biochemical Recurrence, High Risk Biochemical Recurrence of Non-metastatic Castration-sensitive Prostate Cancer, Non-metastatic Castration-sensitive Prostate Cancer.
What interventions are being tested in trial NCT06555796?
The interventions under investigation include: Xaluritamig (DRUG).
Who is sponsoring clinical trial NCT06555796?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06555796 being conducted?
This trial has 11 study locations across Minnesota, New York, North Carolina, Oregon, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prostate Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
Study of JANX007 in Subjects With Metastatic Castration-Resistant Prostate Cancer (ENGAGER-PSMA-01)
RECRUITING · Phase 1
-
Study of STM-416p Administered to Patients Undergoing Radical Prostatectomy
RECRUITING · Phase 1
-
A Study to Learn How Safe AZD6621 is, How Well it Works, and How it Moves Throughout the Body Over Time, in Adult Male Participants With Metastatic Prostate Cancer
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.